Examples of using Denosumab in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Denosumab was found to be at least equivalent to zoledronate in a large multicenter clinical trial on patients with castration-refractory prostate cancer.
Standard tests to investigate the genotoxicity potential of denosumab have not been evaluated,
Prolia contains denosumab, a protein(monoclonal antibody)
Reproductive toxicity was shown in a study of cynomolgus monkeys, dosed throughout pregnancy with denosumab at AUC exposures 119-fold higher than the human dose see section 5.3.
In a single phase III placebo-controlled clinical trial in patients with prostate cancer receiving ADT an imbalance in diverticulitis adverse events was observed 1.2% denosumab, 0% placebo.
the degree of renal impairment had no effect on the pharmacokinetics of denosumab.
Denosumab displayed non-linear pharmacokinetics with dose over a wide dose range,
Patients being treated with Prolia should not be treated concomitantly with other denosumab- containing medicinal products for prevention of skeletal related events in adults with bone metastases from solid tumours.
Denosumab has been designed to attach to an antigen called RANKL,
XGEVA contains denosumab, a protein(monoclonal antibody)
Influenza-like illness was reported with a crude incidence rate of 1.2% for denosumab and 0.7% for placebo.
In neonatal rats, inhibition of RANKL(target of denosumab therapy) with high doses of a construct of osteoprotegerin bound to Fc(OPG-Fc)
There were no clinically-relevant alterations in trough serum concentration and pharmacodynamics of denosumab(creatinine adjusted urinary N- telopeptide,
Denosumab appears to be at least as well tolerated as the bisphosphonates.
These preliminary data suggest that denosumab might be an effective treatment for osteoporosis.
A trial in mice has shown that the drug denosumab could become a preventative breast cancer….
The fully human monoclonal antibody denosumab(formerly known as AMG 162)
In lab tests reported in the journal Nature Medicine, denosumab blocked the growth of the cancer precursor cells
Researchers found that the osteoporosis drug, denosumab, can halt the growth of cells which give rise to breast tumours in women whose risk of the disease is greater because of mutations in a gene called BRCA1.
prevent complications(e.g. denosumab for the treatment/prevention of osteolysis)